Switch theme
Sign up to access all valuation multiples
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir which is a collagen wrap used in peripheral nerve repair; and OrthoACI an implantation used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline such as Tendon Cell Therapy and Collagen Medical Device Platform.
2006
n/a
LTM Revenue $4.8M
LTM EBITDA -$3.5M
$205M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Orthocell has a last 12-month revenue of $4.8M and a last 12-month EBITDA of -$3.5M.
In the most recent fiscal year, Orthocell achieved revenue of $3.3M and an EBITDA of -$7.3M.
Orthocell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Orthocell valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.7M | $3.3M | XXX | XXX | XXX |
| Gross Profit | $0.5M | $2.0M | XXX | XXX | XXX |
| Gross Margin | 20% | 61% | XXX | XXX | XXX |
| EBITDA | -$6.5M | -$7.3M | XXX | XXX | XXX |
| EBITDA Margin | -244% | -220% | XXX | XXX | XXX |
| Net Profit | -$5.7M | -$3.9M | XXX | XXX | XXX |
| Net Margin | -215% | -118% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Orthocell's stock price is AUD 1 (or $1).
Orthocell has current market cap of AUD 357M (or $224M), and EV of AUD 327M (or $205M).
See Orthocell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $205M | $224M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Orthocell has market cap of $224M and EV of $205M.
Orthocell's trades at 43.0x LTM EV/Revenue multiple, and -59.4x LTM EBITDA.
Analysts estimate Orthocell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Orthocell and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $205M | XXX | XXX | XXX |
| EV/Revenue | 46.3x | XXX | XXX | XXX |
| EV/EBITDA | -38.7x | XXX | XXX | XXX |
| P/E | -54.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -38.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOrthocell's NTM/LTM revenue growth is 72%
Orthocell's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Orthocell's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Orthocell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Orthocell and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -120% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -47% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 58% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 68% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 163% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 299% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Orthocell acquired XXX companies to date.
Last acquisition by Orthocell was XXXXXXXX, XXXXX XXXXX XXXXXX . Orthocell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Orthocell founded? | Orthocell was founded in 2006. |
| Where is Orthocell headquartered? | Orthocell is headquartered in Australia. |
| Is Orthocell publicy listed? | Yes, Orthocell is a public company listed on ASX. |
| What is the stock symbol of Orthocell? | Orthocell trades under OCC ticker. |
| When did Orthocell go public? | Orthocell went public in 2014. |
| Who are competitors of Orthocell? | Similar companies to Orthocell include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Orthocell? | Orthocell's current market cap is $224M |
| What is the current revenue of Orthocell? | Orthocell's last 12-month revenue is $4.8M. |
| What is the current EBITDA of Orthocell? | Orthocell's last 12-month EBITDA is -$3.5M. |
| What is the current EV/Revenue multiple of Orthocell? | Current revenue multiple of Orthocell is 43.0x. |
| What is the current EV/EBITDA multiple of Orthocell? | Current EBITDA multiple of Orthocell is -59.4x. |
| What is the current revenue growth of Orthocell? | Orthocell revenue growth between 2023 and 2024 was 25%. |
| Is Orthocell profitable? | Yes, Orthocell is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
